SAN DIEGO, October 8 /PRNewswire/ --

- Company Announces Corporate Restructuring to Focus on Strategic Alliances and M&A

Nventa Biopharmaceuticals Corporation (TSX: NVN), a company developing innovative therapeutics for the treatment of viral infections and cancer, today provided an update on its ongoing development programs. The company also announced that it will initiate a corporate restructuring that will extend the company's financial resources to pursue near-term corporate development opportunities, sale of specific programs, M&A and alternative financial arrangements to maximize the value of its assets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

WALTON OAKS, England, October 9 /PRNewswire/ --

WALTON OAKS, England, October 9 /PRNewswire/ --

- Glaucoma Leading Cause of Preventable Blindness in the UK(1) Though Awareness of Symptoms and Risk Factors Remains Low

Today on World Sight Day leading experts aim to raise awareness of the eye disease glaucoma. It is estimated that there are currently up to 500,000 people in England and Wales who are at risk of losing their sight due to undiagnosed glaucoma(2) despite the condition being the leading cause of preventable blindness in the UK(1).

SAN MATEO, California and READING, England, October 8 /PRNewswire/ --

Avistar Communications Corporation (Nasdaq: AVSR), a video collaboration platform provider, today announced that Beyondis, a Reading, U.K.-based distributor of Voice over IP and videoconferencing products, will offer Avistar's patent protected C3 desktop technology to its resellers throughout the U.K. This move enables Beyondis resellers to offer a deeper product line to their customers, who have been requesting desktop videoconferencing as a way to enhance their communications abilities among their employees.

ASHLAND, Massachusetts, October 8 /PRNewswire/ --

- Acceptance Will Reduce Animal Use in Cosmetics and Chemicals Testing

MatTek Corp. today announced that results of a recently completed US and European multi-laboratory "catch-up" validation study on MatTek's EpiDerm in vitro human skin tissue equivalent. The test results demonstrated the required sensitivity and specificity for EpiDerm to be accepted as a validated alternative to animal testing for determining human skin irritation by the European ECVAM Scientific Advisory Committee (ESAC).

IRVINE, California, October 8 /PRNewswire/ --

- New Game in Development

GamersFirst (http://www.gamersfirst.com), a service of K2 Network and one of today's most popular free-to-play online game publishers, announces a development partnership for an original game with A2M, the largest independent game developer in Canada.

GamersFirst and A2M will be working together on an unannounced social gaming title. This new game will be available in late 2009 and continues the pledge of GamersFirst expanding its industry presence into the development of original titles.

COPENHAGEN, October 8 /PRNewswire/ --

- Review Zanolimumab Program to be Discontinued and Headcount to be Reduced

- Summary: Genmab Announces the Results of its Portfolio Review; Zanolimumab Program to be Discontinued and the Company Will Reduce the Number of Employees

Genmab A/S (OMX: GEN) announced today that it is discontinuing development of zanolimumab (HuMax-CD4(R)). In addition, as a result of a portfolio review and assessment of the organization, Genmab is reducing its headcount by 101 positions.